Abstract:Objective: This study aimed to systematically review the status and trends of Chinese clinical practice guidelines (CPGs) during the time period 2010–2020 and explore their methodological characteristics. Then, based on the strengths and weaknesses in development, offer several recommendations for the quality improvement which will serve as a reference for the users and developers of CPG. Introduction: With the development of evidence-based medicine (EBM), the CPGs play an increasingly important role in healthcare decision-making both in China and worldwide. Inclusion criteria: The CPGs that have been used to help the health professionals in the healthcare decision-making were included. Methodology: The China National Knowledge Infrastructure (CNKI) and WanFang databases were searched from 2010 to 2020 for the studies describing the general and methodological characteristics of Chinese CPGs. Comparisons of the methodological characteristics between the groups were conducted using the chi-square test or Fisher's exact test. The M-K test was adopted to identify the monotonically increasing or decreasing trends of methodological characteristics over the timespan. Results: A total of 2,654 CPGs fulfilled the inclusion criteria. The quantity and quality of the guidelines developed in China have improved over the time span. From 2010 to 2020,the guidelines had differing characteristics and covered a wide range of subjects. In total, 2,318(87.34%) guidelines focused on Western Medicine. Eight (0.30%) had been developed for patient versions of guidelines, 10(0.38%) were tentative guidelines, and 16(0.60%) were rapid advice guidelines. Medical specialty societies (including their branches) (71.1%) were the main guideline makers. The most addressed diseases were neoplasms (14.43%). The target population is mainly adults (84.97%). The methodological quality of consensus-based (CB)-CPGs was obviously lower than evidence-based (EB)-CPGs. Except for the item, “recommendations were based on evidence of systematic reviews,” there were statistical differences in all other methodological items between the EB-CPGS and CB-CPGS ( P < 0.01). Higher methodological quality has been observed in EB-CPGs. All the data relating to the methodological characteristics indicated that higher methodological quality was present in the guidelines using GRADE ( P < 0.01). Conclusion: The quantity and quality of the guidelines developed in China have improved between 2010 and 2020. CB-CPGs have also paid attention to the methodology quality, but obviously, this is lower than that in the EB-CPGs.

[Developing process of guide on methodological standards in pharmacoepidemiology (T/CPHARMA 002-2019)].

[Report standards for clinical comprehensive evaluation of Chinese patent medicine]

[Pharmacovigilance guidelines for clinical application of oral Chinese patent medicines]

[Guideline for clinical comprehensive evaluation of Chinese patent medicine (2022 version)]

Analysis of the Status and Trends of Chinese Clinical Practice Guideline Development Between 2010 and 2020: A Systematic Review

[Guidelines for post-marketing research on clinical effectiveness of Chinese patent medicines]

[Guidelines for construction of traditional Chinese medicine pharmacovigilance system in medical institutions]

[Pharmacovigilance guidelines of Chinese patent medicines]

The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM

[Guidelines for Economic Evaluation of Post-Marketing Chinese Patent Medicine].

Health Technology Assessment and Its Use in Drug Policies in China

Guideline for postmarketing Chinese medicine pharmacoeconomic evaluation

Clinical practice guidelines of Chinese patent medicine in China: A critical review

[Expert consensus on pharmacoeconomic evaluations alongside clinical trials (2024 edition)]

Technical specifications for hospital-based intensive monitoring of post-marketing Chinese patent medicine

[Interpretation for the Group Standards in Technical Specification of Management for Field Survey in Large Population-Based Cohort Study].

Exposure Protection Countermeasures for Novel Coronavirus Infection in Hospital Pharmaceutical Staff

Guideline for [clinical Guidelines Constitution/Amendment] in China.

[Clinical application evaluation and revision suggestions of clinical practice guideline on traditional Chinese medicine therapy alone or combined with antibiotics for community acquired pneumonia]

Establishment of RWS guidance reflecting contributions of China to regulatory science

How Well Did the Consensus Methods Apply in the Guideline Development of Traditional Chinese Medicine: a Web-Based Survey in China